+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Obsessive-Compulsive Disorder (Central Nervous System) - Drugs in Development, 2021

  • PDF Icon

    Drug Pipelines

  • March 2021
  • Region: Global
  • Global Markets Direct
  • ID: 5331260
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Obsessive-Compulsive Disorder - Drugs in Development, 2021, provides an overview of the Obsessive-Compulsive Disorder (Central Nervous System) pipeline landscape.

Obsessive-compulsive disorder (OCD) is characterized by unreasonable thoughts and fears (obsessions) that lead to do repetitive behaviors (compulsions). Symptoms include having repeated thoughts or images about many different things, such as fear of germs, dirt, or intruders, acts of violence, hurting loved ones, doing the same rituals over and over such as washing hands, locking and unlocking doors, counting, keeping unneeded items, or repeating the same steps again and again. Risk factor includes family history. Treatment includes antidepressants and psychiatric medications.

Report Highlights


The publisher's Pharmaceutical and Healthcare latest pipeline guide Obsessive-Compulsive Disorder - Drugs in Development, 2021, provides comprehensive information on the therapeutics under development for Obsessive-Compulsive Disorder (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Obsessive-Compulsive Disorder (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Obsessive-Compulsive Disorder and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 2, 4 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Obsessive-Compulsive Disorder (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope


  • The pipeline guide provides a snapshot of the global therapeutic landscape of Obsessive-Compulsive Disorder (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Obsessive-Compulsive Disorder (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Obsessive-Compulsive Disorder (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Obsessive-Compulsive Disorder (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Obsessive-Compulsive Disorder (Central Nervous System)

Reasons to Buy


  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Obsessive-Compulsive Disorder (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Obsessive-Compulsive Disorder (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Introduction
  • Report Coverage

Obsessive-Compulsive Disorder - Overview
Obsessive-Compulsive Disorder - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes

Obsessive-Compulsive Disorder - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type

Obsessive-Compulsive Disorder - Companies Involved in Therapeutics Development
  • Amorsa Therapeutics Inc
  • Biogen Inc
  • Biohaven Pharmaceutical Holding Company Ltd
  • Cannabis Science Inc
  • Octapharma AG
  • Omeros Corp
  • Phytecs
  • Rugen Therapeutics R&D (Shanghai) Co Ltd
  • Seropeutics LLC
  • Sumitomo Dainippon Pharma Co Ltd

Obsessive-Compulsive Disorder - Drug Profiles
CBISOCD-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

DSP-1181 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

immune globulin (human) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

OMS-527 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

PECS-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

psilocybin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

rituximab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

SERx-480 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

Small Molecules to Antagonize GRIN2B for Autism and Obsessive Compulsive Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

Small Molecules to Target NMDA Receptor for Obsessive Compulsive Disorder - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

troriluzole hydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress

Obsessive-Compulsive Disorder - Dormant Projects
  • Obsessive-Compulsive Disorder - Discontinued Products

Obsessive-Compulsive Disorder - Product Development Milestones
  • Featured News & Press Releases
  • Jan 04, 2021: Biohaven begins pivotal Phase 3 trial of troriluzole in obsessive-compulsive disorder
  • Jun 24, 2020: Biohaven announces obsessive compulsive disorder (OCD) proof of concept phase 2/3 study results and program update
  • Jan 30, 2020: Sumitomo Dainippon Pharma, Exscientia advance AI drug candidate
  • Sep 16, 2019: Omeros announces positive results from phase 1 study of its lead PDE7 inhibitor in development for addiction
  • Dec 21, 2017: Biohaven Enrolls First Patient In Pivotal Trial Of Trigriluzole In Patients With Obsessive-Compulsive Disorder
  • Oct 24, 2017: Biohaven Receives FDA May Proceed Letter for Phase 2/3 Clinical Trial of Trigriluzole in Patients with Obsessive-Compulsive Disorder
  • Jul 13, 2017: Biohaven Receives Notice Of Allowance From U.S. Patent And Trademark Office On Patent Application For Glutamate Modulating Prodrugs
  • Mar 19, 2013: Omeros Elucidates Mechanism Of PDE7 Inhibitors In Addiction

Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact the Publisher
  • Disclaimer

List of Tables
  • Number of Products under Development for Obsessive-Compulsive Disorder, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Obsessive-Compulsive Disorder - Pipeline by Amorsa Therapeutics Inc, 2021
  • Obsessive-Compulsive Disorder - Pipeline by Biogen Inc, 2021
  • Obsessive-Compulsive Disorder - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, 2021
  • Obsessive-Compulsive Disorder - Pipeline by Cannabis Science Inc, 2021
  • Obsessive-Compulsive Disorder - Pipeline by Octapharma AG, 2021
  • Obsessive-Compulsive Disorder - Pipeline by Omeros Corp, 2021
  • Obsessive-Compulsive Disorder - Pipeline by Phytecs, 2021
  • Obsessive-Compulsive Disorder - Pipeline by Rugen Therapeutics R&D (Shanghai) Co Ltd, 2021
  • Obsessive-Compulsive Disorder - Pipeline by Seropeutics LLC, 2021
  • Obsessive-Compulsive Disorder - Pipeline by Sumitomo Dainippon Pharma Co Ltd, 2021
  • Obsessive-Compulsive Disorder - Dormant Projects, 2021
  • Obsessive-Compulsive Disorder - Discontinued Products, 2021

List of Figures
  • Number of Products under Development for Obsessive-Compulsive Disorder, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Amorsa Therapeutics Inc
  • Biogen Inc
  • Biohaven Pharmaceutical Holding Company Ltd
  • Cannabis Science Inc
  • Octapharma AG
  • Omeros Corp
  • Phytecs
  • Rugen Therapeutics R&D (Shanghai) Co Ltd
  • Seropeutics LLC